Genen­tech yanks Gavre­to's rare thy­roid can­cer in­di­ca­tion, months be­fore hand­ing it back to Blue­print

Roche sub­sidiary Genen­tech is yank­ing Gavre­to’s ac­cel­er­at­ed ap­proval for a type of thy­roid can­cer af­ter de­ter­min­ing a con­fir­ma­to­ry study is no longer fea­si­ble.

The ki­nase in­hibitor, al­so known as pralse­tinib, will no longer be avail­able to adults and kids 12 years and up with ad­vanced or metasta­t­ic re­arranged dur­ing trans­fec­tion (RET)-mu­tant medullary thy­roid can­cer (MTC), Genen­tech’s part­ner Blue­print Med­i­cines re­vealed in an SEC fil­ing Fri­day. The an­nounce­ment comes just a few months af­ter Genen­tech said it would hand Gavre­to’s rights back to Blue­print, end­ing a years­long col­lab­o­ra­tion ef­fec­tive next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER